Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.130
+0.010 (0.89%)
At close: Oct 23, 2026, 4:00 PM EDT
1.131
+0.001 (0.04%)
After-hours: Oct 23, 2026, 5:32 PM EDT
Alzamend Neuro Employees
As of July 31, 2026, Alzamend Neuro had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees did not change since the number was last reported on April 30, 2026. That makes Alzamend Neuro the 41,378th largest employer in the world and 6,379th in the United States.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,516,117
Market Cap
5.45M
Employees Chart
| Date | Employees | Change | Growth | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jul 31, 2026 | 6 | 0 | - | 4 | 2 |
| Apr 30, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Apr 30, 2025 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2024 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Apr 30, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Senti Biosciences Holdings | 39 |
| Longeveron | 38 |
| Cardio Diagnostics Holdings | 17 |
| Traws Pharma | 7 |
| Lexaria Bioscience | 7 |
| Can-Fite BioPharma | 5 |
| Acurx Pharmaceuticals | 4 |
ALZN News
- 5 weeks ago - Alzamend Neuro regains Nasdaq compliance - TheFly
- 6 weeks ago - Alzamend Neuro Quarterly report: Q1 2027 - Filings
- 1 month ago - Alzamend Neuro Proxy statement: Proxy filing - Filings
- 2 months ago - Alzamend Neuro registers to sell 98.39M shares of common stock for holders - TheFly
- 2 months ago - Alzamend Neuro Registration statement: Registration filing - Filings
- 2 months ago - Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PRNewsWire
- 2 months ago - Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - PRNewsWire
- 2 months ago - Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - PRNewsWire